Premium
Dual Stimuli‐Responsive Nanoparticles for Controlled Release of Anticancer and Anti‐inflammatory Drugs Combination
Author(s) -
Feng Liandong,
Wang Yuqi,
Luo Zhiliang,
Huang Zheng,
Zhang Yan,
Guo Kai,
Ye Deju
Publication year - 2017
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201701524
Subject(s) - doxorubicin , multiple drug resistance , pharmacology , drug delivery , drug , cancer cell , chemistry , rational design , controlled release , targeted drug delivery , nanoparticle , combination therapy , cancer , nanotechnology , chemotherapy , medicine , materials science , biochemistry , antibiotics , organic chemistry
Dual stimuli‐responsive nanoparticles capable of fine‐tuning drug release to augment therapeutic efficacy have become a promising tool for anticancer drug delivery. However, the rational design of these “smart” nanoparticles for a selective delivery and controlled release of multidrug combinations in cancer cells to achieve synergistic effects remain challenging. Here we report the pH/redox dual responsive nanoparticle FA‐DOX‐Ind‐NP (FA=folic acid, DOX=doxorubicin, Ind=indomethacin, NP=nanoparticle) based on the novel tumor targeting and biodegradable poly(β‐amino ester) polymer, and demonstrate its high ability to enter into cancer cells and release a combination of the anticancer drug doxorubicin and the non‐steroidal anti‐inflammatory drug indomethacin to achieve synergistic chemo‐anti‐inflammatory effects and overcome multidrug resistance. This study highlights the great potential of tumor targeting and dual stimuli‐responsive nanoparticles for an efficient delivery of multidrug combination to improve the cancer therapeutic efficacy.